Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recent developments in myelodysplastic syndromes

    ... approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald a new era in the ...

    Research Article last updated 04/29/2016 - 11:34am.

  2. Personalized medicine for MDS

    ... treatment for MDS.  The classic example is the use of lenalidomide for patients with a del (5q) abnormality.  -In recent ... and the average length of response is 2 years.  -Lenalidomide works best in patients with red blood cell transfusion ...

    Research Review last updated 05/02/2016 - 9:44am.

  3. Myelodysplastic syndromes: Contemporary review and how we treat

    ... (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, allogeneic stem ...

    Research Article last updated 04/29/2016 - 1:05pm.

  4. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

    ... Purpose:  The drugs, lenalidomide , bortezomib, and dexamethasone, are approved by the FDA. They ... approved by the FDA for the treatment of multiple myeloma. Lenalidomide is approved for use with dexamethasone for patients with multiple ...

    Clinical Trial last updated 05/23/2016 - 3:45pm.

  5. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or ... that a majority of such patients who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, ...

    Research Review last updated 05/02/2016 - 9:32am.

  6. Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

    ... The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be ... Associated Drug(s):  Lenalidomide Phase:  ...

    Clinical Trial last updated 04/29/2016 - 10:40am.

  7. Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

    ... research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment formyelodysplastic syndrome (MDS) or ... to determine the safety and efficacy of the bortezomib and lenalidomide investigational combination. This drug combination has been used ...

    Clinical Trial last updated 04/28/2016 - 10:20am.

  8. Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome

    ... This phase II trial studies how well lenalidomide and eltrombopag olamine works in treating patients ... in low or intermediate myelodysplastic syndrome. Lenalidomide may stimulate the immune system in different ways and stop cancer ...

    Clinical Trial last updated 04/28/2016 - 10:10am.

  9. Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    ... This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa ... patients with myelodysplastic syndrome and anemia . Lenalidomide may stop the growth ofmyelodysplastic syndrome by blocking blood ...

    Clinical Trial last updated 04/27/2016 - 9:59am.

  10. Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (UF-BMT-MRD-101)

    ... side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of ... Associated Drug(s):  Lenalidomide Phase:  ...

    Clinical Trial last updated 04/29/2016 - 2:38pm.